ARPO

Aerpio Pharmaceuticals Inc

A clinical-stage biopharmaceutical company that develops medicines for vascular and eye diseases, working on therapies that target the Tie2 pathway to treat conditions like diabetic macular edema and glaucoma. It came out of Akebia Therapeutics as a spinoff focused on vascular biology, with its name rooted in the vessel-related research at its core. Its lead experimental drug, AKB-9778, was developed to help keep blood vessels in the eye healthy and stable.

No Schedule 13D or 13G filings recorded.